Last reviewed · How we verify
Priorix Tetra TM 208136
Priorix Tetra TM 208136 is a vaccine Biologic drug developed by GlaxoSmithKline. It is currently in Phase 3 development for Measles, mumps, rubella, and varicella prevention. Also known as: MMRV.
Priorix Tetra is a vaccine that stimulates the body's immune response to protect against measles, mumps, rubella, and varicella.
Priorix Tetra TM 208136 is a vaccine that protects against Acellular Pertussis, Tetanus, Diphtheria, and Poliomyelitis. It is a small molecule vaccine, classified as a small molecule modality according to ChEMBL.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Anti-infectives pathway favourability
+2.0pp
Microbiological endpoints + non-inferiority designs raise approval rates above baseline. -
Big-pharma sponsor
+3.0pp
GlaxoSmithKline is a top-20 pharma sponsor — historical approval rates run ~3pp above average due to scale, regulatory experience, and trial-design quality.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Priorix Tetra TM 208136 |
|---|---|
| Also known as | MMRV |
| Sponsor | GlaxoSmithKline |
| Drug class | vaccine |
| Modality | Biologic |
| Therapeutic area | Infectious Diseases |
| Phase | Phase 3 |
Mechanism of action
It works by introducing weakened or inactivated forms of the viruses to the body, which triggers an immune response and helps the body develop immunity against future infections.
Approved indications
- Measles, mumps, rubella, and varicella prevention
Common side effects
- Pain, redness, or swelling at the injection site
- Fever
- Fatigue
Key clinical trials
- Immunogenicity and Safety of Boostrix Polio Vaccine as a Booster Dose in 5 to 6-year-old Children. (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Priorix Tetra TM 208136 CI brief — competitive landscape report
- Priorix Tetra TM 208136 updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI
Frequently asked questions about Priorix Tetra TM 208136
What is Priorix Tetra TM 208136?
How does Priorix Tetra TM 208136 work?
What is Priorix Tetra TM 208136 used for?
Who makes Priorix Tetra TM 208136?
Is Priorix Tetra TM 208136 also known as anything else?
What drug class is Priorix Tetra TM 208136 in?
What development phase is Priorix Tetra TM 208136 in?
What are the side effects of Priorix Tetra TM 208136?
Related
- Drug class: All vaccine drugs
- Manufacturer: GlaxoSmithKline — full pipeline
- Therapeutic area: All drugs in Infectious Diseases
- Indication: Drugs for Measles, mumps, rubella, and varicella prevention
- Also known as: MMRV
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing